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The cerebral microvessel endothelium forming the blood-brain barrier (BBB) and the
epithelium of the choroid plexuses forming the blood-CSF barrier (BCSFB) operate as
gatekeepers for the central nervous system. Exposure of the vulnerable developing brain
to chemical insults can have dramatic consequences for brain maturation and lead to
life-long neurological diseases. The ability of blood-brain interfaces to efficiently protect
the immature brain is therefore an important pathophysiological issue. This is also key
to our understanding of drug entry into the brain of neonatal and pediatric patients.
Non-specific paracellular diffusion through barriers is restricted early during development,
but other neuroprotective properties of these interfaces differ between the developing
and adult brains. This review focuses on the developmental expression and function of
various classes of efflux transporters. These include the multispecific transporters of
the ATP-binding cassette transporter families ABCB, ABCC, ABCG, the organic anion
and cation transporters of the solute carrier families SLC21/SLCO and SLC22, and
the peptide transporters of the SLC15 family. These transporters play a key role in
preventing brain entry of blood-borne molecules such as drugs, environmental toxicants,
and endogenous metabolites, or else in increasing the clearance of potentially harmful
organic ions from the brain. The limited data available for laboratory animals and human
highlight transporter-specific developmental patterns of expression and function, which
differ between blood-brain interfaces. The BCSFB achieves an adult phenotype earlier than
BBB. Efflux transporters at the BBB appear to be regulated by various factors subsequently
secreted by neural progenitors and astrocytes during development. Their expression is
also modulated by oxidative stress, inflammation, and exposure to xenobiotic inducers.
A better understanding of these regulatory pathways during development, in particular
the signaling pathways triggered by oxidative stress and xenobiotics, may open new
opportunities to therapeutic manipulation in view to improve or restore neuroprotective
functions of the blood-brain interfaces in the context of perinatal injuries.
Keywords: blood-brain barrier, choroid plexus, development, ABC transporter, SLC transporter, perinatal injury,
hypoxia, xenobiotic
INTRODUCTION
Blood-brain interfaces comprise the cerebral microvessel
endothelium forming the blood-brain barrier (BBB) and the
epithelium of the choroid plexuses forming the blood-CSF
barrier (BCSFB). These interfaces operate as gatekeepers for the
central nervous system, hence providing the cerebral homeostasis
necessary for normal neuronal growth and activity.
During brain development, these CNS barriers display
stage specific properties. For instance, in rat, the activity of
gamma-glutamyl-transferase, an enzymatic marker of brain
Abbreviations: BBB, blood-brain barrier; BCSFB, blood-CSF barrier; ABC, ATP-
Binding Cassette; OATP, organic anion transport polypeptide; HNF-4 α, hepatic
nuclear factor 4α; Nrf2, nuclear factor erythroid 2-related factor 2; AhR, aryl
hydrocarbon receptor; CAR, constitutive androstane receptor; PXR, pregnane X
receptor.
microvessels, continuously increases from birth to adulthood
(Betz and Goldstein, 1981; Gazzin et al., 2008). Conversely, the
metabolic barrier to DOPA mediated by DOPA-decarboxylase is
most effective in young animals (Betz andGoldstein, 1981). Blood
to brain influx of pyruvate, lactate and β-hydroxybutyrate, as well
as large neutral amino acids is greater in suckling rats compared
to adult animals, while active efflux of amino acids across the BBB
may not occur before 21 days of age (review in Betz andGoldstein,
1981). In the choroid plexus epithelium, the composition in tight
junction proteins changes during brain development. Notably,
expression of the pore-forming claudin-2 is upregulated and that
of the tightening claudin-3 is downregulated, probably reflecting
perinatal changes in inorganic anion transport and related CSF
secretion rate at the BCSFB (Kratzer et al., 2012). These vari-
ous examples illustrate changes in barrier functions that occur
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to face specific needs of the brain at different developmental
stages.
The vulnerability of the developing brain to chemical insults,
especially during the late prenatal/early postnatal period (herein
referred to as perinatal period) can have dramatic consequences
for brain maturation, leading to life-long neurological diseases
(Kaindl et al., 2009; Landrigan and Goldman, 2011; Miodovnik,
2011). The ability of blood-brain interfaces to efficiently protect
the immature brain is therefore a major pathophysiological issue.
It is also key to our understanding of therapeutic drug entry into
the brain of neonate and pediatric patients. Little is known about
the mechanisms protecting the developing brain from harmful
compounds and regulating the cerebral entry of pharmacolog-
ically active compounds. The cerebral interstitial fluid concen-
tration of xenobiotics is set by their ability to cross the brain
endothelium and the choroidal epithelium, as well as a number
of other parameters. These include protein binding, local cere-
bral capillary density and cerebral blood flow, intraparenchymal
diffusion rate, movement by fluid flow along perivascular spaces
and within ventricular and cisternal spaces, and CSF turnover
(reviewed in Ghersi-Egea et al., 2009; Westerhout et al., 2011).
These parameters change during development. Plasma protein
concentration is lower during development than in adult, so are
cerebral blood flow and capillary density (Caley and Maxwell,
1970; Nehlig et al., 1989). Intracerebral fluid dynamic differs
between adult and developing brain. CSF turnover increases at
birth, and the total CSF (cisternal, subarachnoid, and ventricular)
to brain volume ratio is largely higher in perinatal brain (unpub-
lished data). Taken together, these observations indicate that the
impact of blood-CSF exchanges on the overall cerebral bioavail-
ability of drugs or toxic compounds is likely to bemore important
in young than in adult individuals. At the level of the BBBs
proper, the neuroprotective functions result from intercellular
tight junctions sealing the barrier cell layers, as well as detoxifi-
cation enzymes and efflux transporters located in the barrier cells
(Strazielle and Ghersi-Egea, 2013). It is now clearly established
that non-specific paracellular diffusion through the cerebral
endothelium and the choroidal epithelium is efficiently restricted
by the tight junctions early during development (Liddelow et al.,
2013).
This review focuses on efflux transporters and analyses the
data relative to their developmental pattern of localization,
expression and function. These multispecific transport systems
play a key role in preventing the entry into the brain and
CSF of numerous blood-borne xenobiotics, including drugs, or
in increasing the clearance of potentially harmful organic ions
from the brain. They include ATP-Binding Cassette (ABC) trans-
porters of the ABCB, ABCC, and ABCG families, solute car-
riers for organic anions and cations of the SLC21/SLCO and
SLC22 families, and peptide transporters of the SLC15 family 1
(Figure 1). These efflux transporters also recognize biologically
active endogenous compounds, including steroid hormones and
eicosanoids (leukotrienes, prostaglandins), thus protecting the
1Capitalized characters are used when referring to human transporters or
to transporters listed in a general context. Minor characters are used when
specifically referring to rodent transporters.
brain from a potentially deleterious overproduction of these
compounds.
ATP-BINDING CASSETTE TRANSPORTERS
Multispecific efflux transporters that belong to the ABC trans-
porter superfamily and are found in blood-brain interfaces
include ABCB1 (P-glycoprotein), ABCG2 (breast cancer resis-
tance protein, Bcrp), and several ABCCs (multidrug-related resis-
tance proteins, Mrp) (Schinkel et al., 1996; Nishino et al., 1999;
Wijnholds et al., 2000; Cooray et al., 2002; Strazielle and Ghersi-
Egea, 2013). Located at the blood-facing membranes they prevent
brain penetration of their substrates by an energy-dependent,
unidirectional, outwardly directed transport mechanism. They
are responsible for the efflux of many structurally unrelated
lipophilic and amphiphilic environmental toxic compounds or
drugs, including anti-inflammatory, immunosuppressive, anti-
infectious, and antineoplastic drugs, some antiepileptic, antide-
pressant and psychotropic agents, and drug conjugates in the
case of ABCCs (Schinkel and Jonker, 2003; Leslie et al., 2005;
Staud and Pavek, 2005; Strazielle and Ghersi-Egea, 2005). These
ABC transporters are differentially localized between the two
main blood-brain interfaces (Figure 1). ABCB1 and ABCG2 are
highly expressed at the BBB, while ABCC1 is a landmark of the
BCSFB (Daood et al., 2008; Gazzin et al., 2008). Abcc2 has been
described in the rodent BBB (e.g., Wang et al., 2014), and Abcc4
expression and function have been described in both interfaces in
mice (Leggas et al., 2004). Species differences are found, namely
for ABCG2 which is likely to play a more important protec-
tive function in human than in rodent (Shawahna et al., 2011),
and ABCB1, which is encoded by a single gene in human and
2 genes in rat and mouse. Species difference may also exist for
ABCC2 whose expression at the BBB in normal human brain
is still an open question (Kubota et al., 2006; Dauchy et al.,
2008).
Several studies suggest that ABC transporters are already func-
tional at the blood-brain interfaces in neonates, but that their
expression is developmentally regulated in a protein- and barrier-
specific manner.
Developmental pattern of ABCB localization, expression and
activity at blood-brain interfaces
In mouse and rat, the Abcb1-dependent phenotype of mul-
tidrug resistance is associated with 2 genes Abcb1a and Abcb1b,
both homologs to the human ABCB1 transporter gene. Abcb1a
and Abcb1b are expressed in a tissue-specific manner, and also
differ to some extent in their transport properties. Abcb1a is
closer to the human transporter in terms of amino acid primary
sequence and gene regulatory region, and is the predominant
gene expressed at the BBB. Its expression is already detectable
in endothelial cells in the neural tube of 10.5-day-old mouse
embryos (Qin and Sato, 1995). Immunohistochemical analysis
performed with different antibodies on human tissues showed
that Abcb1 protein consistently localizes at the membrane of
brain microvessels by mid-gestation. Before this stage, the signal
is heterogeneous and displays regional differences (Schumacher
and Mollgard, 1997; Virgintino et al., 2008). Accordingly, Gazzin
and coll. reported that this transporter is present in rat brain
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FIGURE 1 | Schematic representation of the main multispecific
transporters involved in neuroprotective efflux at the blood-brain
(left) and blood-CSF (right) barriers. Underlined names represent
transporters for which evidence has also been reported in human. The
ATP-dependency is shown only for primary ATP-dependent transporters.
Transporters in parenthesis are carriers for which evidence of their
involvement in CNS-blood efflux processes is still limited. See text for
references. TJ, tight junction.
microvessels at birth, a developmental stage which corresponds
to preterm development in human (Gazzin et al., 2008). As
would be required for its neuroprotective efflux function, Abcb1
immunoreactivity was found at the luminal membrane of the
endothelial wall. Because the cerebral capillary density increases
greatly during development, the amount of Abcb1 protein at
the BBB cannot be compared between stages using total brain
homogenates. A standard curve-based quantitative Western blot
analysis performed on isolated microvessels showed that the
amount of Abcb1 in the BBB in 9- and 17-day-old rats was
only one-fifth of that found in microvessels isolated from adult
animals (Gazzin et al., 2008, 2011). This is in agreement with
the more intense immunohistochemical signal observed in brain
microvessels from adult as compared to perinatal or postnatal
developmental stages in human, rat or mouse (Matsuoka et al.,
1999; Tsai et al., 2002; Daood et al., 2008; Gazzin et al., 2011). It
is also consistent with the 3-to-4-fold increase in Abcb1a mRNA
levels measured in endothelial cells from adult mice or rats com-
pared to levels in endothelial cells of developing animals (2- to
8-day-old mouse, 14-day-old rat) (Daneman et al., 2010a; Harati
et al., 2012a). The low expression and protein level of Abcb1
observed at the BBB in different species at late prenatal and early
postnatal developmental stages may therefore result in a weaker
protection of the brain against circulating compounds that are
handled by this transporter. Accordingly, a 80–90% lower brain
accumulation of cyclosporin A and digoxin, assessed as brain-
blood/plasma ratio 2 h following administration, was observed
in adult mice compared with 1-day-old mice, a difference which
was abolished in Abcb1a deficient animals (Goralski et al., 2006).
A number of other functional studies have been conducted using
digoxine as Abcb1 substrate. A greater accumulation of this
molecule was observed in the brain of 15.5-day-old embryonic
mice compared to the brain of 18.5-day-old embryonic mice
(Petropoulos et al., 2010). In rat, the unbound brain-to-plasma
concentration ratio of the molecule measured at steady-state was
not different between 3-week- and 12-week-old animals (Harati
et al., 2012a). A positron emission tomography study conducted
in rhesus monkeys showed a significantly higher clearance value
for verapamil uptake in 9-month-old animals than in 2- and 4-
year-old animals (Takashima et al., 2011). With the reservation
that substrate specificities for Abcb1 are not absolute, in particu-
lar for digoxin which can be recognized by other transporters such
as Slco1a4/oatp2, overall, these partial data suggest that ABCB1
functional activity parallels gene expression levels, both increas-
ing from prenatal to pre-adult stages in various animal species,
including non-human primates.
The amount of ABCB1 protein in rat and human choroid
plexus is low by comparison to the levels measured in brain
microvessels (Gazzin et al., 2008), and its cellular and subcellu-
lar localization within the choroidal tissue is subject to conflictual
results. Its implication in the regulation of exchanges across the
BCSFB is likely limited. In contrast to the BBB, Abcb1a mRNAs
are not detected by RT-PCR in the BCSFB. The gene expressed in
rat choroid plexus is Abcb1b. The level of expression, very low in
adult rat tissue, is 4–8 times higher during the perinatal period
of development, with a peak on postnatal day 2 (Kratzer et al.,
2013). The actual functional activity of the transporter and the
significance of this perinatal upregulation of choroidal Abcb1b
expression are not known.
Developmental pattern of ABCG2 localization, expression and
activity at blood-brain interfaces
There are few data available on the developmental expression of
ABCG2, but there is a general agreement that the transporter
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is associated with the brain vasculature and localizes at the
luminal membrane of brain endothelium early during develop-
ment, specifically by week 22 of gestation in human (Daood et al.,
2008), embryonic day 12.5 in mouse and in rat (Tachikawa et al.,
2005; Orford et al., 2009; Ek et al., 2010). No apparent differ-
ence in signal intensity was observed throughout development in
these studies. Only a moderate (2-fold or less) increase in Abcg2
mRNA levels was observed in endothelial cells isolated from adult
vs. postnatal mouse brain (Daneman et al., 2010a) or between
cerebral capillary preparations of comparable purity isolated from
14-day-old rats vs. adult animals (Harati et al., 2012a). In the lat-
ter study no difference in Abcg2 protein level was observed by
Western blot between the two stages. Functional studies on Abcg2
mediated transport during development have been performed
only in rat on postnatal day 21. At that stage, blood-to-brain pra-
zosin transport was not different from that measured in adult rats
(Harati et al., 2012a). Overall, ABCG2 seems to reach high levels
of expression at the BBB early during development. It may com-
pensate for the lack of Abcb1-dependent protection at a period of
high brain vulnerability.
Studies on the expression and function of Abcg2 in choroid
plexus generated apparently conflicting results, possibly linked
to species differences, or due to difficulties in achieving specific
immunolabeling in this tissue. The level of protein assessed by
Western blot is clearly much lower in choroidal tissue than in
brain capillaries, as illustrated in the work performed by Reichel
and colleagues in rat (Reichel et al., 2011). They loaded 10
times more proteins from choroidal tissue than from microves-
sels to be able to detect Abcg2 in the former sample, while the
capillary fraction yielded an intense signal. In line with that
report, an immunohistochemical study conducted on human
tissue failed to detect ABCG2 in the choroid plexus at any devel-
opmental stage (extending from 22 weeks of gestation to adult),
while the transporter was clearly detected in the microvascu-
lature (Daood et al., 2008). Using transgenic mice expressing
GFP under the control of Abcg2 promoter/enhancer sequences,
Orford and colleagues showed that the transporter is associ-
ated with choroidal vessels from early on during development
but not with the choroidal epithelium (Orford et al., 2009).
By contrast, the protein was detected at the apical membrane
of the choroidal epithelium in adult mouse, a signal that was
not seen in Abcg2 knock-out animals (Tachikawa et al., 2005;
Zhuang et al., 2006). No developmental data was provided in
these studies. Other studies failed to detect the protein in choroid
plexus epithelium of the adult rat (Roberts et al., 2008; Ek et al.,
2010). One of the latter studies reported Abcg2 immunoreac-
tivity at the basolateral membrane of the choroidal epithelium
only at early developmental stages (embryonic day 15 and post-
natal day 1) (Ek et al., 2010). This pattern of Abcg2 protein
expression in rat parallels the temporal profile of choroidal
Abcg2 mRNA levels which are also higher in pre- and perina-
tal stages than in adult (Ek et al., 2010; Kratzer et al., 2013).
It has to be noted that mRNA levels are low in choroid plexus
in both rat and mouse (Tachikawa et al., 2005; Kratzer et al.,
2013). Overall, if Abcg2 has any significant transport function
at the BCSFB, it should be especially relevant to the developing
period.
Developmental localization, expression and activity of efflux
transporters of the ABCC family at blood-brain interfaces
An immunohistochemical signal for ABCC1 was consistently
observed in human choroid plexus epithelium early in gestation,
from week 22 onwards (Daood et al., 2008). In rat, Abcc1 protein
was detected in choroid plexus epithelial cells as early as embry-
onic day 15, with a basolateral localization consistent with its
efflux transporter activity and a neuroprotective function (Gazzin
et al., 2008; Ek et al., 2010). Choroidal mRNA levels were 2-
to 3-fold lower in 15-day-old embryos and 7-day-old rat pups
than in adult (Ek et al., 2010; Kratzer et al., 2013), but at birth,
protein levels measured by quantitative Western blot are similar
to those in adult (Gazzin et al., 2008), suggesting that Abcc1-
mediated efflux at the BCSFB is active early during development.
Protein and mRNA levels of Abcc1 are low in both the rodent and
human microvasculature in comparison to choroidal levels, and
the actual localization and efflux activity of the protein at the BBB
proper remains controversial (reviewed in Gazzin et al., 2008).
One study investigated ABCC1 protein in the human BBB during
development and failed to detect the transporter at any devel-
opmental stage (Daood et al., 2008). Only rat mRNA expression
data are available concerning the developmental pattern of other
Abcc transporters. In the choroid plexus, the temporal expres-
sion profile for Abcc4, for which functional evidence of transport
has been provided in vivo in adult mice (Leggas et al., 2004),
follows a developmental pattern similar to that of Abcc1, with
a limited increase in mRNA level in adult tissue compared to
tissue from embryonic day 19. As in choroid plexus, mRNA lev-
els in brain endothelial cells are moderately (3.3 times) lower in
young mice (postnatal day 2–8) than in adult animals (Daneman
et al., 2010a). The concurrent expression of this transporter in the
BCSFB and the BBB from early stages on, and its polarized local-
ization at blood-facing membranes in both barriers suggest that it
plays an important role in the clearance of endogenous substrates
in young and adult individuals.
Abcc5, Abcc9, and Abcc10 genes investigated in rat choroid
plexus are expressed at a similar or higher level in developing ani-
mals compared to adults (Kratzer et al., 2013). Functionally, an
Abcc-dependent basolateral efflux of intracellularly formed drug
conjugates has been demonstrated in freshly isolated choroid
plexuses or in choroid plexus epithelial cells, both obtained
from 2-day-old rats (Strazielle and Ghersi-Egea, 1999; Ghersi-
Egea et al., 2006). These ex vivo/in vitro studies indicated that
one or several Abcc proteins are efficiently participating to a
neuroprotective enzymatic BCSFB during development.
SOLUTE CARRIER PROTEINS
The SLC superfamily comprises virtually all transporters that
do not belong to the ABC family. Multispecific SLC trans-
porters responsible for the neuroprotective efflux of exogenous
and endogenous toxic molecules from brain or CSF to blood
belongmainly to three subfamilies. The SLC22 subfamily includes
organic anion and cation efflux transporters also referred to as
OAT, OCT, and OCTN proteins. SLCO transporters, previously
known as SLC21 form another subfamily of organic anion trans-
port polypeptides (OATPs). Of note, several SLCO rodent genes
have no homologs in human, and vice-versa. SLCO and SLC22
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transporters accept as substrates a broad range of cationic and
anionic compounds, including environmental pollutants, and
various drugs such as antibiotics and nucleosidic antiviral drugs,
non-steroidal anti-inflammatory agents, and some antiepilep-
tic drugs. They also transport steroid or drug conjugates, and
lipid mediators (Strazielle et al., 2003; Hagenbuch and Stieger,
2013; Koepsell, 2013). Finally, members of the SLC15 fam-
ily, known as peptide/proton cotransporters, transport in addi-
tion to endogenous di- and tripeptides, some peptidomimetic
drugs, e.g., β-lactam antibiotics, antiviral nucleoside prodrugs
or angiotensin converting enzymes (Daniel and Rubio-Aliaga,
2003).
Some of these solute carriers are bidirectional. Others func-
tion as unidirectional inwardly-directed multispecific transport
systems and exchange their substrates with specific intracel-
lular divalent organic anions by a coupled secondary energy-
dependent mechanism. SLC transporters that are involved in
brain efflux localize at the abluminal (BBB) or apical (BCSFB)
membrane of barrier cells, where they remove drugs and toxic
compounds from brain extracellular and CSF spaces. The most
documented SLC efflux transporters at blood-brain interfaces are
the following. SLC22A8/OAT3 is present at both brain endothe-
lial cells and choroidal epithelial cells in rodents, and is also
detected in human choroid plexus (Nagata et al., 2002; Alebouyeh
et al., 2003; Kikuchi et al., 2003; Mori et al., 2003; Ose et al.,
2009). Slco1a5/Oatp3, Slc15a2/Pept2, and possibly Slc22a2/Oct2
are restricted to choroid plexus (Kusuhara et al., 2003; Ohtsuki
et al., 2003). Other organic anion transporters are found at
blood-brain interfaces, but their possible involvement in brain
efflux rather than influx processes remaining to be established
(Figure 1). Slco1a4/oatp2 is found at both luminal and abluminal
membranes of brain endothelial cells, and only at the basolat-
eral membrane of the choroidal epithelium in rat (Gao et al.,
1999). In human, two SLCO3A1 variants v1 and v2, of similar
and broad substrate specificity, are respectively located on the
basolateral and apical membranes of the choroidal epithelium,
suggesting that SLCO3A1 may function both as an influx and an
efflux transporter (Huber et al., 2007). SLCO1A2 and SLCO2B1,
also expressed at the human BBB, are likely to mediate brain
influx rather than brain efflux, on the basis of their localization
at the luminal membrane of the endothelium (Gao et al., 2000;
Bronger et al., 2005).
Developmental localization, expression and activity of SLC22 and
SLCO efflux transporters at blood-brain interfaces
Data on the developmental expression of efflux transporters that
belong to the SLC22 and SLCO gene families are scarce and
obtained only from rat and mouse studies. Transcriptomic anal-
ysis of endothelial cells isolated from adult vs. postnatal mouse
brains suggests that developmental profiles are heterogeneous
among genes (Daneman et al., 2010a). While mRNA levels for
Slc22a5 (octn2) and Slco1a4 were 2-to 5-fold lower in endothe-
lial cells from developing animals compared to adults, Slc22a8
expression was similar at both stages. Slc22a17 and Slco2b1,
whose precise functions are currently unknown at brain bar-
riers, did not display developmental changes either. Of note
in this study, the mRNA levels of Slco2a1, the prostaglandin
transporter with an unknown directionality of transport, were
much higher at the BBB from developing vs. adult mice. This
suggests a developmentally regulated mechanism for blood-brain
exchange of prostaglandins, possibly related to the function of
these lipid mediators in brain maturation. In rat, a lower expres-
sion was reported for Slco1a4 between developing and adult
animal, while there was no change for Slc22a8 (Harati et al.,
2012a). This was assessed by quantitative PCR and Western blot
on isolated capillaries and confirms the mouse transcriptomic
observations.
The analysis of transcriptomic profiles established in rat
choroid plexus for 14 Slco and Slc22 members showed that most
genes, including Slc22a5, Slco1a4, and Slco1a5 are expressed at
similar or higher levels during the perinatal period than at the
adult stage. One exception is Slc22a8, for which expression levels
are respectively 4-fold and 2-fold lower in 19-day-old embryos
and 2-day-old rats than in adults. At an earlier stage, in 15-
day-old embryos, gene expression levels relative to adult were
more heterogeneous (Kratzer et al., 2013). A functional analy-
sis showed that ex vivo uptake of bromosulfophthalein, a typical
Slco substrate, was 3-fold higher in choroid plexuses isolated
from newborn rat compared to adult rat (Angeletti et al., 1998).
Western blot and immunohistochemical localization of Slco were
also performed in this study, but are difficult to interpret as, at
that time, Slco1a5 was mistakenly identified as Slco1a1 in this
tissue. As further evidence of organic anion transport maturity
at the BCSFB, choroidal epithelial cells isolated from newborn
rats efficiently mediate the transport of Slc22 and Slco substrates
such as 2,4-dichlorophenoxyacetic acid, benzylpenicillin, zidovu-
dine or taurocholate in an unidirectional CSF-to-blood direction
(Strazielle et al., 2003).
Developmental localization and expression of SLC15 efflux
transporters at the choroid plexus
Amongmembers of the SLC15 family, Slc15a2 is well expressed in
the brain, with the highest level in the choroid plexus (Shen et al.,
2004). Both mRNA levels and immunohistochemical signals for
Slc15a2 were similar in rat choroid plexuses at perinatal and adult
stages (Shen et al., 2004; Kratzer et al., 2013). The apical localiza-
tion of this choroidal transporter suggests its efficacy in exporting
neuropeptides, peptide fragments, and peptide-like drugs out of
CSF from early on during brain development.
The overall developmental profiles of all ABC and SLC efflux
transporters reviewed above are summarized in Table 1. It shows
that regarding the expression of efflux transporters, an overall
adult-like phenotype is reached earlier at the BCSFB than at
the BBB.
REGULATION OF EFFLUX TRANSPORTER ASSOCIATED BARRIER
PROPERTIES DURING DEVELOPMENT
Signaling pathways involved in the early specification of brain
barrier cells have been identified in the last decade, point-
ing out a few molecular cues that specifically regulate the
developmental expression of efflux transporters. In addition,
these transport systems are modulated in disease and by vari-
ous xenobiotics via mechanisms that may bear developmental
specificities.
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Table 1 | Comparative analysis of the developmental expression pattern of efflux transporters between the blood-brain- and blood-CSF
barriers.
Blood-brain barrier Blood-CSF barrier
Major efflux transporters Developmental pattern Major efflux transporters Developmental pattern
ABCB1/Abcb1a ↗ mRNA, Prot, Fc Abcc = Fc
ABCG2/Abcg2 = mRNA, (Prot) Abcc1 = mRNA, Prot
Abcc4 ↗ mRNA Abcc4 ≤ mRNA
Slc22a8 = mRNA, Prot Slc22a8 ↗ mRNA
Slco ↘ Fc
Slco1a5 = mRNA
Pept2/Slc15 = mRNA (Prot)
Other multispecific transporters Developmental pattern Other multispecific transporters Developmental pattern
Slc22a5 ↗ mRNA Abcb1b ↘ mRNA
Slco1a4 ↗ mRNA, Prot Abcg2 ↘ mRNA (Prot)
Slc22a17 = mRNA Abcc5 = mRNA
Slco2b1 = mRNA Abcc9 ↘ mRNA
Slco2a1→ ↘ mRNA Abcc10 = mRNA
Slc22a5 = mRNA
Slco1a4 = mRNA
↗, ↘, = increased, decreased, similar expression in adult as compared to neonatal stages, respectively. mRNA, assessed by qRTPCR or gene array. Prot, assessed
by quantitative western blot. (Prot), assessed by immunohistochemical signal intensity. Fc, assessed by functional studies, using specific substrates. For references,
see text.
Pathways involved in the developmental regulation of efflux
transporters at blood-brain interfaces
The unique phenotype of brain microvessel endothelial cells
compared to other endothelia in the body has long ago raised
the hypothesis that surrounding neural cells were responsible for
inducing BBB characteristics. A series of grafting experiments
generated controversial results regarding this theory (reviewed in
Bauer and Bauer, 2000). Arguments in favor of a role for adja-
cent cells, notably astrocytes emerged from many in vitro studies.
It was thought for example, that the BBB hallmark transporter
Abcb1 was under astrocytic regulation on the basis that its expres-
sion and functionality, which are partially lost in brain microves-
sel endothelial cells in culture were reinduced in endothelial cells
co-cultured with glial cells. However, because of the temporal pat-
tern of neural cell differentiation and the late apparition ofmature
astrocytes which in rat andmouse occurs only around birth, these
cells obviously cannot impart the inducing signals that trigger
BBB formation in neovessels. Astrocytes nonetheless are essential
later for further maturation of the BBB (see infra), or for main-
tenance of its properties as suggested by the link between some
astrocyte diseases and BBB dysfunction (Keller, 2013).
A large number of studies have recently been directed toward
identifying the molecules, pathways, and cells responsible for
CNS specific vascular differentiation. The Wnt/β-catenin canon-
ical pathway has emerged as a prominent signaling mechanism,
promoting angiogenesis and concurrently inducing hallmark fea-
tures of the BBB, such as the expression of the glucose transporter
Slc2a1 (reviewed in Liebner et al., 2011). Wnt factors are secreted
as early as embryonic day 9 by neural progenitors. The vari-
ous studies dedicated to this topic did not examine the direct
effects of Wnt signaling on the expression of ABC and SLC
efflux transporters at the BBB. DNA binding sites for T cell
factor/lymphoid enhancer-binding factor TCF/LEF, the transcrip-
tional activating factor downstream of the Wnt/β-catenin path-
way, are present in the human ABCB1 gene promoter (Yamada
et al., 2000). Functional evidence linking β-catenin accumula-
tion with intestinal expression of the human ABCB1 gene or
the mouse Abcb1a gene has been reported in intestinal cells
(Scotto, 2003). Regarding the BBB, activation of β-catenin sig-
naling by GSK-3 inhibition in the human brain endothelial cell
line hMEC/D3 as well as in rat brain endothelial cells in primary
culture similarly increased ABCB1 expression and function (Lim
et al., 2008). The expression of ABCC4 and ABCG2 genes was also
modulated in the hMEC/D3 cells in response to β-catenin signal-
ing activation or inhibition, suggesting that the early embryonic
expression of Abcg2 described in rat and mouse could depend
on the same regulatory pathway. Although direct evidence in the
embryonic brain is lacking, these data support the idea that the
range of genes associated with the BBB phenotype and induced
by the canonical Wnt pathway in newly formed cerebral ves-
sels include efflux transporters. Other regulatory mechanisms are
expected to add on this triggering mechanism to explain the
different profiles observed among efflux transporters, such as
between Abcb1 and Abcg2 for example (see supra).
Retinoic acid, a potent morphogen directing the development
of the nervous system, has been proposed as another signaling
cue contributing to the induction of the specific BBB phenotype
at an early stage of angiogenesis. In human fetal brain, radial glial
cells express the final enzyme involved in retinoic acid biosyn-
thesis, while endothelial cells express one of the receptors for
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this signaling factor (Mizee et al., 2013). Treatment of mice from
day 10.5 to day 16.5 of gestation with a retinoic acid receptor
antagonist led to the downregulation of several BBB distinct prop-
erties in embryos, in particular to a decrease in the expression
level of Abcg2 gene. One limitation of this result was that RNA
levels were measured on the whole brain including a priori the
choroid plexus as well as the subventricular zone, both regions
of the brain that express the Abcg2 gene at substantial levels dur-
ing this period. It is possible that the decrease observed in treated
embryos on day 16.5 may not reflect changes at the BBB per se,
but rather in either one or both of these regions (Orford et al.,
2009). Immunostaining of Abcg2 in these animals should clarify
this point.
In addition to neural progenitors and radial glial cells, peri-
cytes are present in the early phase of cerebral angiogenesis, and
are recruited by the nascent vessels invading the neuroectoderm.
Amajor role of pericytes in influencing the endothelial phenotype
has been clearly demonstrated in vivo for a number of features,
including the loss of transcytotic vesicles, or the induction of
the glucose transporter Slc2a1 (Armulik et al., 2010; Daneman
et al., 2010b). By contrast, transcript levels for Abcb1a and Abcg2
in endothelial cells of 18-day-old mouse embryos did not differ
between pericyte deficient Pdgfrb-/- animals and littermate con-
trols (Daneman et al., 2010b), suggesting that initial induction of
these efflux transporters is not under pericyte control.
Because similar deletion of astrocytes in vivo is not possible,
current evidence for the influence of these cells on the differ-
entiated status of BBB endothelial cells has been gathered using
culture systems. One bias in these in vitro studies arises from the
fact that endothelial cells are isolated from adult brain, thus with
an already mature phenotype, and they downregulate some of
their BBB-specific properties. For that reason, astrocytic effects
observed in vitromay reflect not onlymaturation processes occur-
ring when these cells appear, but also repair mechanisms triggered
under pathological conditions. With regard to efflux transporters,
the focus has been mainly on ABCB1. Its protein level and func-
tion are increased in endothelial cells cocultured with astrocytes,
compared to endothelial cells alone (see for example Fenart et al.,
1998; Gaillard et al., 2000). This reinduction occurs in the absence
of any direct contact between the two cell populations, inferring
the role of astrocytic soluble factors. Some of these astrocyte-
derived molecules that act on endothelial receptors to promote
BBB-specific properties have been identified (Abbott et al., 2006;
Alvarez et al., 2011, for a review). They include sonic hedge-
hog ligands, angiopoietin 1 which is a ligand for the endothelial
Tie2 tyrosine kinase receptor, or TGF-β1.Their role on the expres-
sion and function of ABC and SLC efflux transporters still need
to be evaluated in vivo, using animals deficient for these path-
ways or pharmacological inhibition approaches. Evidence for the
role of these signaling molecules in regulating the expression and
activity of efflux transporters has been provided in other cell
types. For example, activation of the sonic hedgehog pathway
associates with elevated therapeutic resistance in cancer cells, in
part due to increased protein level and activity of both ABCB1
and ABCG2 (Sims-Mourtada et al., 2007). Consistently, the pro-
moter region of the ABCG2 gene contains a binding site for
the downstream transcription factor Gli and is a direct target of
sonic hedgehog signaling (Singh et al., 2011). Tie2 activation also
promotes a chemoresistance phenotype in gliomas by inducing
ABCB1 expression level and activity (Martin et al., 2009), and
TGF-β1-mediated increase in Abcb1 expression and activity has
been demonstrated in guinea pig brain endothelial cells in culture
(Baello et al., 2014).
If significant progress has been achieved in the understand-
ing of how the BBB gains its distinct phenotype, the signaling
pathways responsible for the early specification of the choroidal
epithelium vs. ependyma remain obscure, in particular concern-
ing the regulation of expression of Slc and Abcc genes. The hepatic
nuclear factor 4α (HNF-4α) is a key regulator of differentiation in
the liver or the intestine, where it stimulates in particular the tran-
scription of drug metabolizing enzymes and efflux transporters.
HNF-4α is expressed in choroid plexus epithelial cells in rat and
human at the adult stage, and can bind to regulatory sites in the
ABCC1 gene promoter (Niehof and Borlak, 2009). Further work
is needed to confirm its potential role in controlling the early
choroidal-specific transcription of Abcc1.
Modulation of efflux transporters in response to injury and
environmental insults during development
The pathogenesis of perinatal injuries most frequently involves
hypoxia/ischemia, maternal-fetal infection or inflammation
(Aden et al., 2010). These insults are associated with the secretion
of proinflammatory cytokines, as well as oxidative/electrophilic
stress for which the neonatal brain shows a selectively high
susceptibility (Ferriero, 2001). Neuroprotective genes including
anti-oxidant genes and efflux transporter genes of the ABC and
SLC families are known to be regulated by these stress signals
as part of the coordinated defense mechanisms implemented by
the cells in response to oxidative stress. The regulatory path-
ways involve transcription factors that generally act as sensors
in the cytoplasm and translocate to the nucleus to increase the
transcription of target genes. Oxidative species and the lack of
oxygen can be sensed by the nuclear factor erythroid 2-related
factor 2 (Nrf2) and the hypoxia inducible factor 1alpha HIF-1α,
respectively. There is mounting evidence that these stress sensing
factors are expressed and functional in cells of the blood-brain-
interfaces. Nrf2-dependent signaling increases Abcb1, Abcg2, and
Abcc2 expression levels in rat brain microvessels, and accordingly
decreases brain uptake of verapamil, a substrate of Abcb1 (Wang
et al., 2014). The efficacy of Nrf2 signaling in improving neuro-
protection at the microvasculature during brain development has
not been explored. The functionality of the Nrf2-dependent path-
way at the BCSFB was assessed in vitro, in choroidal epithelial
cells, through Nrf2 translocation in the nucleus upon isothio-
cyanate treatment and transcriptional upregulation of down-
stream genes (e.g., heme oxygenase, Xiang et al., 2012). It is
notable that in rat choroid plexus, Nrf2, HIF-1α, and HIF-1β
display a strikingly steady expression from embryonic day 15 to
the adult stage (Kratzer et al., 2013). We can therefore specu-
late that the choroid plexus will react to oxidative/electrophilic
and hypoxic stresses at least, by increasing neuroprotective genes
at the BCSFB early during development. Yet, this needs further
investigation, since hypoxia/ischemia in 9-day-old mice did not
change the level of expression of Abcc1 in the choroid plexus,
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although other target genes for Nrf2, such as heme oxygenase or
glutathione-S-transferase a1 were strongly upregulated (D’Angelo
et al., 2013). This suggests that Nrf2 signaling is functional in the
choroid plexus of young animals, but that not all target genes
are equally sensitive at that stage, or share the same kinetic of
induction.
Regarding the consequences of inflammatory challenges on
efflux transporters, Abcb1 regulation has been investigated in
details in freshly isolated rat capillaries (reviewed in Hartz and
Bauer, 2010). Its expression and functional activity in adult is
differently modulated by short term and long term exposure to
pro-inflammatory stimulus. The extent and direction of change in
ABCB1 expression is also disease-specific (reviewed in Stolp et al.,
2013). During development, inflammation-associated changes in
BBB efflux transporters can be stage-dependent. For instance,
Abcb1 and Abcg2 efflux function at the BBB increase in response
to endothelin-1 in adult, but not in juvenile (21-day-old) rats.
This difference may be related to the lower cytokinic response of
the BBB to endothelin-1 treatment in juvenile compared to adult
animals (Harati et al., 2012b). More work is needed to delineate
the role of inflammation in the regulation of efflux transporters
at the BBB during development, and the actual window of sus-
ceptibility. The choroid plexus is very sensitive to inflammatory
challenges, rapidly responding through increased secretion of
inflammatory mediators including chemoattractants and pro-
inflammatory cytokines. Exposure of the choroidal epithelium
in vitro to activated immune cells or cytokines leads to a decrease
in CSF-to-blood efflux of prostaglandin E2, a transport process
which is likely mediated by SLC and ABC efflux transporters
(Khuth et al., 2005; Batisson et al., 2006). Little is known so far
on the regulation of efflux transporters in vivo at the BCSFB in
the context of perinatal inflammation. Changes in such transport
mechanisms that set the CSF levels of different biologically active
endogenous organic anions including prostanoids may have dra-
matic consequences for brain development and maturation, and
deserves further exploration.
In different peripheral organs such as the liver, exposure to
environmental toxicants or food components can activate addi-
tional transcription factors belonging to the nuclear factor family,
which in turn trigger the induction of protective genes includ-
ing efflux transporter genes. Among these xenosensors, the aryl
hydrocarbon receptor (AhR), the constitutive androstane recep-
tor (CAR), or the pregnane X receptor (PXR) have efflux trans-
porters among their target genes (see Scotto, 2003 for a review
of the mechanisms involved). Current knowledge about these
nuclear receptors indicates that they are expressed in cells of the
blood-brain interfaces in animals and human. AhR is expressed
in human brain microvessels, while additional expression of PXR
and CAR genes has been reported for the rodent BBB (Dauchy
et al., 2008; Hartz and Bauer, 2010). Upon ligand activation,
these nuclear factors were shown to induce the expression and/or
function of Abcb1, Abcc2, or Abcg2 (reviewed in Hartz and
Bauer, 2010). It is still unknown whether nuclear receptors are
expressed and modulate efflux transporters at the BBB during
development.
In choroid plexus, gene expression can be detected for a wide
range of these transcription factors in prenatal, postnatal, and
adult stages of rat development, and their role in the coordinated
induction of detoxifying enzymes and transporters at the BCSFB
has been suggested (Kratzer et al., 2013).
CONCLUSION
The current limited data available in the literature reveal
transporter-dependent developmental profiles of expression in
blood-brain interfaces both in laboratory animals and in human.
The developmental pattern of a given transporter can also differ
between the BBB and the BCSFB (Table 1). The BCSFB achieves
an “adult-like” phenotype earlier than the BBB. For instance, in
the latter, Abcb1 displays a major increase in expression postna-
tally. On the basis of recent studies on early BBB differentiation,
we can speculate that neural progenitors and radial glial cells
have a major role in triggering the endothelial expression of
certain efflux transporters via Wnt and retinoic acid signaling.
This would provide some degree of protection against deleteri-
ous compounds to the developing brain. Once vascular networks
have formed, newly generated astrocytes induce further differ-
entiation of the BBB, through the sonic hedgehog pathway. The
concept of barrier immaturity during brain development may
therefore hold for selected efflux transporters at the BBB. This
novel view of a restricted barrier capacity of the developing brain
endothelium is independent from the efficacy of its tight junc-
tions sealing the paracellular pathway, which is established early
during prenatal development. It needs to be taken into account
when neonatal and pediatric treatments are discussed. The devel-
opmental regulation of efflux transporters at the choroid plexus
remains obscure. Further work is needed on the signaling cues
responsible for specifying the choroidal phenotype of the neu-
roepithelium and in particular for governing the expression of
efflux transporter genes.
A number of choroidal ABC transporters, as well as choroidal
and endothelial SLCO transporters display a higher expression or
activity in developing animals than in adults. Additional studies,
tackling especially the functionality and substrate specificity of
these transporters, are necessary to better appreciate the signifi-
cance of their stage-specific expression.
In the context of developmental diseases, aberrations in
one of the signaling pathways that induce efflux transporter-
dependent protective functions in blood-brain interfaces may
lead to substantial changes in fetal/neonatal brain exposure
to undesired substrates, and subsequently alter normal brain
development.
Choroid plexus studies suggest that from early on during
development, brain efflux may be enhanced following expo-
sure to xenobiotic inducers including drugs and environmental
toxins. The modulation of efflux transporter expression and
function by oxidative stress and inflammation often associated
with perinatal injuries deserves further investigation. A better
understanding of the regulatory pathways, in particular the rel-
ative contribution of the different transcription factors sensing
oxidative stress or xenobiotics during development, is clini-
cally relevant. It may open new opportunities for therapeu-
tic manipulation designed to improve or restore blood-brain
interface neuroprotective functions in the context of perinatal
injuries.
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